about
Patient-adjusted versus health professional-adjusted insulin dosing for type 2 diabetes mellitusInsulin detemir versus insulin glargine for type 2 diabetes mellitusComparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analysesInsulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A1chieve studyAssessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin.Development and validation of the Chinese Attitudes to Starting Insulin Questionnaire (Ch-ASIQ) for primary care patients with type 2 diabetesPharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.Continuous subcutaneous insulin infusion in patients with type 2 diabetes: a cohort study to establish the relationship between glucose control and plasma oxidized low density lipoproteinSoluble insulin analogs combining rapid- and long-acting hypoglycemic properties - From an efficient E. coli expression system to a pharmaceutical formulation.A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.Caffeic acid phenethyl amide improves glucose homeostasis and attenuates the progression of vascular dysfunction in Streptozotocin-induced diabetic rats.Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trialGlycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study.Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Intensifying treatment of type 2 diabetes mellitus: adding insulin.Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.Improving Type 2 Diabetes Mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.Efficacy and safety of biphasic insulin aspart 30/70 in type 2 diabetes suboptimally controlled on oral antidiabetic therapy in Korea: a multicenter, open-label, single-arm study.Obese Patients with Type 2 Diabetes on Conventional Versus Intensive Insulin Therapy: Efficacy of Low-Calorie Dietary Intervention.Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy.The impact of the quality of care and other factors on progression of chronic kidney disease in Thai patients with Type 2 Diabetes Mellitus: A nationwide cohort study.Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.Duration of diabetes and effectiveness of insulin in the management of insulin-naïve Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MOdaliTy of Insulin treatment eValuation (MOTIV) registry results.Understanding Experiences of Diabetes Medications Among African Americans Living With Type 2 Diabetes.Perceptions of Insulin Treatment Among African Americans With Uncontrolled Type 2 Diabetes.Antidiabetic Potential of Monoterpenes: A Case of Small Molecules Punching above Their Weight.Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.In VitroandIn Vivoα-Glucosidase and α-Amylase Inhibitory Effects of the Water Extract of Leaves of Pepper (Capcicum AnnuumL. CultivarDangjo) and the Active Constituent Luteolin 7-O-Glucoside
P2860
Q24202547-4320C8E5-D58F-4032-B30D-82906E0FB698Q24235596-E166C2DB-DF12-432C-86FC-6AF27E6A4341Q33585766-5709C983-3590-44A6-B190-C45000920885Q33607759-75E86DEA-431D-4E63-9468-7081D3A6816AQ33902616-594A4482-AAD7-4DC0-902E-D66B1C703C3CQ34229076-0DA11C4A-0136-4340-B2C6-C2EA69BF0900Q34297738-8DB481B1-FA61-4DEC-BE31-C6B1C23EFE83Q35043641-75858B3D-1392-473F-AC36-42B30F7F4002Q35997284-54872E63-DA72-4B97-8FE0-D8BE331AF569Q36158965-C9099D6E-8117-4280-A9CF-1861E7F9A03BQ36308899-E2AD6DBC-0FD6-4233-B895-985F0EE8777DQ36334537-FDA6B036-A5FD-475C-A2A9-A072898BD1DAQ36996537-11CB776A-FA94-4123-BC0A-40288E0E82B4Q37251203-6E8D5474-D86D-42B7-978F-E6CE72F50BE0Q37344032-2361BF5B-8D77-44F6-BE72-47AB3478D939Q37355883-10D68FEB-0BD6-4EC2-878A-E25A49EE7ED5Q37385524-6D455050-481F-4270-8283-DF5DD1D6CBF7Q37588842-36DE7A18-3468-4BB6-9109-21CC7800B679Q37961849-74C3119D-9CB2-40C8-A8F6-B0D25E8E8DF6Q38036770-16A946C8-EB1C-4A4F-B18F-9B9E0A797420Q38529399-83C14967-6C15-4E0B-AB67-C48C165925F3Q38668530-A944EE37-1103-4C4F-910F-7BD22E731D06Q38864019-E3AB9162-7F33-4078-BD96-D4521B213407Q39514706-A45677AE-E382-4A34-962D-33AB86ACCCF1Q40177955-4809B153-0EB1-439E-B949-AE4395F0F99DQ40904806-0442B9B1-25A8-4A02-AB67-32D9A65E54B4Q41847888-644B98B4-251E-40BD-94D9-130638FFE7A7Q42339118-BAD3E610-15AE-496A-B019-6DF72C2E7003Q42619686-F3B42FED-8DB5-4BDE-985C-341596410FFDQ42645710-70DC6F5D-6D68-44F2-A9E6-95B2FF03C30BQ46267026-B9870AB4-CD7C-4298-814D-784736528A21Q46619907-D32EA37F-AC3D-4253-8EB6-54533C6F407FQ47173290-608E61A7-C917-40B4-A40D-16846B0A0854Q47769217-76EC5A85-68E7-497C-9EFE-C9E1F8DC36DFQ51332885-327B7E70-CF36-4F70-B001-9F53D29E1F9FQ56619367-B79399A2-5191-4265-95A6-23567692A9AC
P2860
description
im November 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 2009
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2009
@uk
name
Insulin therapy for type 2 diabetes
@en
Insulin therapy for type 2 diabetes
@nl
type
label
Insulin therapy for type 2 diabetes
@en
Insulin therapy for type 2 diabetes
@nl
prefLabel
Insulin therapy for type 2 diabetes
@en
Insulin therapy for type 2 diabetes
@nl
P2860
P921
P356
P1433
P1476
Insulin therapy for type 2 diabetes
@en
P2093
Joost B Hoekstra
Sanne G Swinnen
P2860
P304
P356
10.2337/DC09-S318
P407
P433
P478
32 Suppl 2
P5008
P577
2009-11-01T00:00:00Z